Xention Raises £8 Million to progress novel heart drugs
Cambridge-based biopharma Xention Ltd – specialising in the discovery and development of ion channel-modulating drugs – has closed an £8 million series D financing.
The proceeds will fund the clinical development of Xention’s novel drugs for the treatment of atrial fibrillation – a major cause of stroke. The company’s interests in this area are focused on two key ion channel targets against which it has already developed a pipeline of selective, novel compounds that are in clinical and pre-clinical development. “We have proven that our technology allows us to discover and develop drug candidates which act on ion channels, an important yet under-exploited class of targets.” said chief executive, Tim Brears. “These funds will allow us to further develop and advance our programmes in atrial fibrillation, an area of substantial unmet medical need”.The financing was led by new investor Seroba-Kernel Life Sciences Ltd and included existing investors Forbion Capital Partners, Crédit Agricole Private Equity, MVM and BTG International.“We are very pleased to have attracted such a high-calibre new investor alongside our existing investors,” said Brears. “We look forward to working closely with Seroba-Kernel and to making full use of their experience and expertise as we further develop our business and execute our strategy of focusing on the development of innovative drugs in the field of cardiac arrhythmia.”Graham Fagg of Seroba-Kernel will join Xention’s board. He said: “As a new investor, we are very excited about the commercial opportunities afforded by Xention. In particular we recognise that Xention’s expertise in the discovery and development of drugs for atrial fibrillation is unrivalled. “The company is led by an experienced management team and fits well within our portfolio of pioneering life science companies.”• PHOTOGRAPH SHOWS: Xention chief executive, Tim Brears